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========================================================

In Table [5](#Taba){ref-type="table"}, the column headings "Grade 3" should be "Grade 3 or 4".

The corrected table is shown here.Table 5Summary of adverse eventsAVAGAST^a^ (*N* = 94)ToGA^b^ (*N* = 50)Total (*N* = 144)All gradesGrade 3 or 4All gradesGrade 3 or 4All gradesGrade 3 or 4*N* (%)*N* (%)*N* (%)*N* (%)*N* (%)*N* (%)Total94 (100)71 (76)50 (100)36 (72)144 (100)107 (74)Hematological toxicities Neutropenia63 (67)45 (48)34 (68)20 (40)97 (67)65 (45) Thrombocytopenia19 (20)2 (2)8 (16)3 (6)27 (19)5 (3) Anemia16 (17)10 (11)11 (22)8 (16)27 (19)18 (13) Febrile neutropenia5 (5)5 (5)3 (6)3 (6)8 (6)8 (6)Non-hematological toxicities Nausea84 (89)18 (19)44 (88)7 (14)128 (89)25 (17) Vomiting60 (64)6 (6)28 (56)2 (4)88 (61)8 (6) Diarrhea51 (54)4 (4)24 (48)2 (4)75 (52)6 (4) Stomatitis34 (36)1 (1)16 (32)1 (2)50 (35)2 (1) Abdominal pain12 (13)1 (1)3 (6)--15 (10)1 (\<1) Hand-foot syndrome54 (57)2 (2)23 (46)1 (2)77 (53)3 (2) Rash19 (20)--5 (10)--24 (17)-- Anorexia83 (88)27 (29)46 (92)10 (20)129 (90)37 (26) Fatigue69 (73)5 (5)26 (52)4 (8)95 (66)9 (6) Peripheral neuropathy28 (30)2 (2)10 (20)--38 (26)2 (1) Renal impairment17 (18)3 (3)27 (54)--44 (31)3 (2) Increased lacrimation2 (2)--1 (2)--3 (2)--^a^The target population of the AVAGAST study was metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction^b^The target population of the ToGA study was HER2-positive metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction

We sincerely apologize for the errors.

The online version of the original article can be found under doi:10.1007/s10120-012-0167-0.
